2. Search Result
Search Result
Results for "

G0/G1-phase

" in MedChemExpress (MCE) Product Catalog:

169

Inhibitors & Agonists

1

Fluorescent Dyes

1

Biochemical Assay Reagents

2

Peptides

27

Natural
Products

1

Isotope-Labeled Compounds

2

Click Chemistry

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17408
    Mevastatin
    Maximum Cited Publications
    7 Publications Verification

    Compactin; ML236B

    		 HMG-CoA Reductase (HMGCR) Bacterial Autophagy Apoptosis Antibiotic Infection Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Mevastatin (Compactin) is a first HMG-CoA reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis, arrests cancer cells in G0/G1 phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment [1] .
    Mevastatin
  • HY-164607
    YL-5092

    		DNA/RNA Synthesis Apoptosis Cancer
    YL-5092 is a selective YT521-B homology (YTH) domain-containing protein 1 (YTHDC1) inhibitor with an IC50 of 7.4 nM and a KD of 29.6 nM. YL-5092 can suppress cancer cell proliferation and induce cell G0/G1 phase arrest and apoptosis. YL-5092 can be used for the research of cancer, such as acute myeloid leukemia (AML) [1].
    YL-5092
  • HY-13680
    Meisoindigo
    2 Publications Verification

    Dian III; N-Methylisoindigotin; Natura-α

    		 Apoptosis Cancer
    Meisoindigo (Dian III), a derivative of Indirubin (HY-N0117), halts the cell cycle at the G0/G1 phase and induces apoptosis in primary acute myeloid leukemia (AML) cells. Meisoindigo exhibits high antitumor activity [1] .
    Meisoindigo
  • HY-15221
    Methylstat
    3 Publications Verification

    		 Apoptosis Histone Demethylase MDM-2/p53 Cardiovascular Disease Cancer
    Methylstat is a potent histone demethylases inhibitor. Methylstat shows anti-proliferative activity with low cytotoxicity. Methylstat induces apoptosis and cell cycle arrest at G0/G1 phase. Methylstat increases the expression of p53 and p21 protein levels. Methylstat inhibits angiogenesis induced by various cytokines. Methylstat can be used as a chemical probe for addressing its role in angiogenesis [1] .
    Methylstat
  • HY-N2414
    Periplogenin
    1 Publications Verification

    		 Reactive Oxygen Species (ROS) Necroptosis Pyroptosis Interleukin Related Caspase NOD-like Receptor (NLR) Neurological Disease Inflammation/Immunology Cancer
    Periplogenin is an orally active cardiac glycoside found in Cortex periplocae. Periplogenin can induce ROS production and necroptosis and cause G0/G1 phase arrest. Periplogenin can inhibit pyroptosis by regulating the NLRP3/Caspase-1/GSDMD signaling. Periplogenin suppresses growth of prostate carcinoma cells by docking to an ATP1A1 protein pocket and forming a hydrogen bond with T804. Periplogenin can be used for the researches of cancer, inflammation and immunology, such as prostate carcinoma, rheumatoid arthritis and psoriasis [1] .
    Periplogenin
  • HY-131906
    JAK2-IN-7

    		JAK FLT3 Apoptosis Cancer
    JAK2-IN-7 is a selective JAK2 inhibitor with IC50s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3 V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities [1].
    JAK2-IN-7
  • HY-N7844
    N6-Benzyladenosine

    Benzyladenosine

    		 Apoptosis Adenosine Receptor Inflammation/Immunology Cancer
    N6-Benzyladenosine is an adenosine receptor agonist, has a cytoactive activity. N6-Benzyladenosine arrests cell cycle at G0/G1 phase and induces cell apoptosis. N6-Benzyladenosine also exerts inhibitory effect on T. gondii adenosine kinase and glioma [1] - .
    N6-Benzyladenosine
  • HY-N9330
    Broussoflavonol F

    		Xanthine Oxidase Cancer
    Broussoflavonol F is a HER2-RAS-MEK-ERK signaling pathway modulator and mushroom tyrosinase inhibitor, with an IC50 of 82.3 μM against mushroom tyrosinase. Broussoflavonol F reduces the protein expression levels of RAS, HER2, phosphorylated BRAF, phosphorylated MEK and phosphorylated Erk. It induces cell apoptosis, triggers G0/G1 phase cell cycle arrest, and exhibits cytotoxicity against colon cancer cells. Broussoflavonol F is applicable to related research on colon cancer [1].
    Broussoflavonol F
  • HY-19350
    BML-210
    2 Publications Verification

    		 HDAC Apoptosis Cancer
    BML-210 is a potent HDAC inhibitor. BML-210 can inhibit the HDAC4-VP16-driven reporter signal with an apparent IC50 of ∼5 µM. BML-210 has a specific disruptive effect on the HDAC4:MEF2 interaction. BML-210 causes an increase in the G0/G1 phase. BML-210 induces apoptosis and displays antitumour activities in orthotopic mammary tumours in mice [1] .
    BML-210
  • HY-146980
    GLUT4-IN-2

    		Apoptosis GLUT Cancer
    GLUT4-IN-2 is a potent and selective GLUT4 inhibitor with IC50s of 11.4 µM and 6.8 µM for GLUT1 and GLUT4, respectively. GLUT4-IN-2 induces cell apoptosis and cell cycle arrest at G0/G1phase. GLUT4-IN-2 shows potent antitumor activity [1].
    GLUT4-IN-2
  • HY-15485
    Zardaverine
    1 Publications Verification

    		 Phosphodiesterase (PDE) Apoptosis Inflammation/Immunology Cancer
    Zardaverine is an orally active and selective PDE3/4 inhibitor (IC50)=0.58 uM/0.17 uM) with potent bronchodilator activity. Zardaverine also selectively inhibits the proliferation of HCC cells and induces apoptosis and cycle arrest (G0/G1 phase). Zardaverine has good antitumor potential and is effective in both bronchial relaxation and reduction of inflammation in asthma [1] .
    Zardaverine
  • HY-N0429
    Diosbulbin B
    1 Publications Verification

    		 Apoptosis MDM-2/p53 Bcl-2 Family CDK Cancer
    Diosbulbin B, a diterpene lactone, is an anticancer agent. Diosbulbin B is an orally active component of Dioscorea. bulbifera L. Diosbulbin B can inhibit cell proliferation, induce G0/G1 phase arrest and apoptosis. Diosbulbin B can induce autophagy and mitochondrial dysfunction. Diosbulbin B can induce liver injury. Diosbulbin B can be used for the research of cancer, such as non-small cell lung cancer (NSCLC) [1] .
    Diosbulbin B
  • HY-114414
    HDACs/mTOR Inhibitor 1
    1 Publications Verification

    		 HDAC mTOR Apoptosis Cancer
    HDACs/mTOR Inhibitor 1 is a dual HDACs and mTOR inhibitor, with IC50s of 0.19 nM, 1.8 nM, 1.2 nM for HDAC1, HDAC6, mTOR, respectively. HDACs/mTOR Inhibitor 1 stimulates cell cycle arrest in G0/G1 phase and induces tumor cell apoptosis with low toxicity in vivo. HDACs/mTOR Inhibitor 1 can be used in the research of hematologic malignancies [1] .
    HDACs/mTOR Inhibitor 1
  • HY-156135
    NSC194598

    		MDM-2/p53 RET DNA/RNA Synthesis Apoptosis Caspase Endocrinology Cancer
    NSC194598 is a p53 DNA-binding inhibitor with an IC50 value of 180 nM. NSC194598 inhibits p53 DNA binding and induction of target genesn when p53 is stabilized and activated by irradiation or chemotherapy. NSC194598 can interfere with transcriptional activation of mutated rearranged during transfection (RET) gene, induce apoptosis and G0/G1 phase arrest. NSC194598 can be used for the researches of acute radiation toxicity and medullary thyroid carcinoma [1] .
    NSC194598
  • HY-143490
    PAK4-IN-2

    		PAK Apoptosis Cancer
    PAK4-IN-2 is a highly potent PAK4 inhibitor with IC50 value of 2.7 nM. PAK4-IN-2 can arrest MV4-11 cells at G0/G1 phase and induce cell apoptosis. PAK4-IN-2 can be used for researching cancer [1].
    PAK4-IN-2
  • HY-10815
    σ1 Receptor antagonist-1
    1 Publications Verification

    		 Sigma Receptor Apoptosis Neurological Disease Cancer
    σ1 Receptor antagonist-1 is a highly potent and selective sigma 1 receptor antagonist (pKi=10.28). σ1 Receptor antagonist-1 inhibits cell growth, arrests cell cycle at G0/G1 phase and induces apoptosis of MCF-7/ADR cells [1].
    σ1 Receptor antagonist-1
  • HY-173557
    PRMT7-IN-2

    		Histone Methyltransferase Apoptosis Cancer
    PRMT7-IN-2 (A33) is a selective PRMT7 inhibitor with an IC50 of 0.50 μM. PRMT7-IN-2 arrests cell cycle at G0/G1 phase, induces cell apoptosis, and inhibits cell growth in vivo and in vitro. PRMT7-IN-2 decreases the monomethylarginine level of PRMT7, increases expression of epithelial marker (E-cadherin, and reduces expression of mesenchymal markers such as N-cadherin, Vimentin, and ZEB2 [1].
    PRMT7-IN-2
  • HY-N1930
    (-)-Hinesol

    Hinesol

    		 Apoptosis Cancer
    (-)-Hinesol (Hinesol) is a potent anticancer agent. (-)-Hinesol induces apoptosis and cell cycle arrest at G0/G1 phase. (-)-Hinesol downregulates MEK/ERK pathway and NF-κB pathway and mediates theexpression of cyclin D1, Bax and Bcl-2. (-)-Hinesol has the potential for the research of non–small cell lung cancer [1].
    (-)-Hinesol
  • HY-149891
    HSP90-IN-23

    		HSP Cancer
    HSP90-IN-23 (Comp 12-1) is an inhibitor of heat shock protein 90(HSP90) with an IC50 of 9 nM. HSP90-IN-23 induces apoptosis of tumor cells and arrests the tumor cell cycle in G0/G1 phase. HSP90-IN-23 can be used for cancer research [1].
    HSP90-IN-23
  • HY-149132
    Dendrogenin A

    DDA

    		 LXR Cancer
    Dendrogenin A (DDA) is a ligand for liver X receptor (LXR), that induces the expression of sodium/iodine symporter, and increases iodine uptake. Dendrogenin A induces cell differentiation of MCF-7, and reactivates the function of lactating cells. Dendrogenin A induces the expressions of the TSH receptor, thyroid peroxidase, and thyroglobulin, and affects thyroid hormone generation. Dendrogenin A exhibits cytotoxicity in cancer cell B-CPAP and 8505c with IC50 of 4.1 and 6.2 µM. Dendrogenin A arrests the cell cycle at G0/G1 phase [1].
    Dendrogenin A
  • HY-W747572
    (+)-Perillyl alcohol

    (R)-(+)-Perillyl alcohol

    		 Ras Cancer
    (+)-Perillyl alcohol is the enantiomer of S-(-)-Perillyl alcohol (HY-116514). (+)-Perillyl alcohol can inhibit the growth of polypeptides and block the cell cycle in the G0/G1 phase. (+)-Perillyl alcohol induces cell signaling that is associated with changes in cytoskeletal actin organization and reduced protein expression of growth regulatory proteins such as Ras and CDC2 kinase [1].
    (+)-Perillyl alcohol
  • HY-N16418
    Epanorin

    		Bacterial Reactive Oxygen Species (ROS) Infection Cancer
    Epanorin is a secondary metabolite of the Acarospora lichenic species Epanorin can inhibit cancer cells proliferation, ROS production and induce G0/G1 phase arrest. Epanorin shows antibacterial activity. Epanorin can be used for the researches of cancer and infection, such as breast cancer and S. pneumonia infection [1] .
    Epanorin
  • HY-174129
    TM471-1

    		Btk Apoptosis Cancer
    TM471-1 is an orally active and covalent Bruton's tyrosine kinase (BTK) inhibitor with IC50 values of 1.3 nM (BTK WT), >40,000 nM (BTK C481S), 7.9 nM (TEC) and 12.4 nM (TXK). TM471-1 inhibits cell growth in vivo and in vitro, arrests cell cycle at G0/G1 phase and induces cell apoptosis [1].
    TM471-1
  • HY-124261
    Sampangine

    		Apoptosis Cancer
    Sampangine is an alkaloid that induces apoptosis by inducing cell cycle arrest in the G0/G1 phase. Sampangine can inhibit the biosynthesis of heme [1] .
    Sampangine
  • HY-144733
    ERα antagonist 1

    		Estrogen Receptor/ERR Apoptosis Cancer
    ERα antagonist 1 (Compound 19d) is a potent, selective, covalent estrogen receptor α (ERα) antagonist. ERα antagonist 1 induces apoptosis and cell cycle G0/G1 phase arrest in MCF-7 cells [1].
    ERα antagonist 1
  • HY-N16567
    Acrofolione A

    		Apoptosis Caspase PARP Survivin Cancer
    Acrofolione A is an acetophenone dimer isolated from Acronychia pendunculata with anticancer effects. Acrofolione A induces G0/G1 phase cell cycle arrest and apoptosis in human NALM-6 pre-B cell leukaemia cells. Acrofolione A can be used for leukaemia research [1].
    Acrofolione A
  • HY-10638
    AP23464

    		c-Kit Apoptosis Cancer
    AP23464 is an ATP-based inhibitor for Kit, that inhibits the phosphorylation of Kit wildtype and mutants, with IC50 of 5-85 nM. AP23464 inhibits the proliferation of Kit mutated cells (IC50 is 3-20 nM), arrests the cell cycle at G0/G1 phase, and induces apoptosis in Kit mutated cells [1].
    AP23464
  • HY-129592
    p-Tolylmaleimide

    		Apoptosis Cancer
    p-Tolylmaleimide (compound 9) is a naphthalimide derivative that has cytotoxic effects on cancer cells. p-Tolylmaleimide can arrest the cell cycle of human acute myeloid leukemia cells K562 in the sub-G0/G1 phase and induce apoptosis [1].
    p-Tolylmaleimide
  • HY-N12044
    Asparanin A

    		Apoptosis Cancer
    Asparanin A is an apoptosis inducer with anticancer activity. Asparanin A induces cell cycle arrest in the G0/G1 phase through mitochondria and PI3K/AKT signaling pathways, inhibiting cancer cell growth. Asparanin A also demonstrated in vivo efficacy in a mouse xenograft model of Ishikawa endometrial carcinoma, significantly inhibiting tumor growth [1].
    Asparanin A
  • HY-122359A
    rel-Levormeloxifene

    rel-L-Centchroman; Ormeloxifene

    		 Estrogen Receptor/ERR Apoptosis Reactive Oxygen Species (ROS) Cancer
    rel-Levormeloxifene (rel-L-Centchroman) is the relative configuration of Levormeloxifene (HY-122359). rel-Levormeloxifene is a selective estrogen receptor modulator (SERM). rel-Levormeloxifene inhibits proliferation of leukemia cells with IC50 about 7 μM, arrests cell cycle at G0/G1 phase, and induces apoptosis. rel-Levormeloxifene induces differentation of myelogenesis leukemia, and enhances ROS production in K562 cells [1].
    rel-Levormeloxifene
  • HY-E70678
    CDK3/CycE1 Recombinant Human Active Protein Kinase

    		CDK Cancer
    CDK3 is a major player driving retinoblastoma (Rb) phosphorylation during the G0/G1 transition and in the early G1 phase of the cell cycle. CDK3 interacts with various transcription factors involved in cell proliferation, differentiation, and transformation driven by the EGFR/Ras signaling pathway. CDK3/CycE1 Recombinant Human Active Protein Kinase is an ortholog of CDK3 [1].
    CDK3/CycE1 Recombinant Human Active Protein Kinase
  • HY-163535
    J208

    		HDAC DNA Methyltransferase Apoptosis Inflammation/Immunology Cancer
    J208 is a dual inhibitor for histone deacetylase (HDAC) and DNA methyltransferase (DNMT). J208 inhibits proliferation of cancer cells, as well as the migration/invasion of triple-negative breast cancer (TNBC) cells. J208 induces apoptosis, arrests the cell cycle at G0/G1 phase. J2008 activates the innate immune signalling pathway in TNBC, by inducing the expression of endogenous retroviruses (ERVs) [1].
    J208
  • HY-17408R
    Mevastatin (Standard)

    Compactin(Standard); ML236B (Standard)

    		 Reference Standards HMG-CoA Reductase (HMGCR) Bacterial Autophagy Apoptosis Antibiotic Infection Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Mevastatin (Standard) is the analytical standard of Mevastatin. This product is intended for research and analytical applications. Mevastatin (Compactin) is a first HMG-CoA reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis, arrests cancer cells in G0/G1 phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment [1] .
    Mevastatin (Standard)
  • HY-168205
    HSP90-IN-33

    		HSP Apoptosis Cancer
    HSP90-IN-33 (compound 24e) is a potent Hsp90 inhibitor with Kd values of ≥200, 7.3 µM for Hsp90α, Hsp90β, respectively. HSP90-IN-33 induces apoptosis and cell cycle arrest at G0/G1 phase. HSP90-IN-33 decreases the protein expression of ERα, CDK4 and Akt [1].
    HSP90-IN-33
  • HY-150688
    JAK3-IN-13

    		JNK Cancer
    JAK3-IN-13 (compound 12n) is a potent, selective and orally active JAK3 inhibitor with IC50 values of 4728, 2039, 8, 365 nM for NK1, JNK2, JNK3, Tyk2, respectively. JAK3-IN-13 shows antiproliferative activity. JAK3-IN-13 induces cell cycle arrest at G0/G1 phase. JAK3-IN-13 shows antitumor activity [1].
    JAK3-IN-13
  • HY-179124
    Apoptosis inducer 52

    		Apoptosis Caspase Cancer
    Apoptosis inducer 52 is a derivative of flutamide that induces apoptosis in prostate cancer cells. Apoptosis inducer 52 promotes apoptosis by activating both intrinsic and extrinsic apoptotic pathways, without generating reactive oxygen species (ROS). Apoptosis inducer 52 triggers caspase 3/7 activity and the externalization of phosphatidylserine, leading to cell cycle arrest at the G0/G1 phase. Apoptosis inducer 52 can be used for the research of androgen receptor (AR)-dependent and -independent prostate cancers and leukemia [1].
    Apoptosis inducer 52
  • HY-115906
    K783-0308

    		FLT3 MNK Apoptosis Cancer
    K783-0308 is a potent and selective dual inhibitor of FLT3 and MNK2 with IC50 values of 680 and 406 nM, respectively. K783-0308 inhibits the growth of MOLM-13 (IC50=10.5 µM) and MV-4-11 (IC50=10.4 µM) cells. K783-0308 promotes acute myeloid leukemia (AML) cell apoptosis and cell cycle arrests in the G0/G1 phase [1].
    K783-0308
  • HY-178350
    MFDCH016

    		CDK HDAC Apoptosis Histamine Receptor Cancer
    MFDCH016 is a potent HDAC1/6 (IC50 = 38/59 nM) and CDK4/6 (IC50 = 680/720 nM) inhibitor. MFDCH016 induces apoptosis and cell cycle arrest in G2/M and G0/G1 phases in MCF-7 cells. MFDCH016 can modulate the HDAC-p21-CDK signaling pathway, increasing the levels of acetylated H3 and p21. MFDCH016 can be used for the study of breast cancer [1].
    MFDCH016
  • HY-174908
    SJL2-1

    		Histone Methyltransferase 11β-HSD Androgen Receptor Cancer
    SJL2-1 is a PRMT5 inhibitor, with an IC50 of 1.56 μM. SJL2-1 suppresses proliferation, migration, and invasion in prostate cancer cells. SJL2-1 promotes apoptosis and blocks the cell cycle at the G0/G1 phase. SJL2-1 can target the binding of PRMT5 in cells and inhibit the methylation and expression of the androgen receptor. SJL2-1 can be used for the study of early androgen-sensitive prostate cancer and advanced castration-resistant prostate cancer (CRPC) [1].
    SJL2-1
  • HY-162416
    CDK7-IN-27

    		CDK Cancer
    CDK7-IN-27 (Compound 37) is a selective inhibitor for cyclin-dependent kinase 7 (CDK7), with Ki of 3 nM. CDK7-IN-27 arrests the cell cycle at G0/G1 phase [1].
    CDK7-IN-27
  • HY-155544
    Antitumor agent-111

    		c-Met/HGFR Cancer
    Antitumor agent-111 (compound 46) is an c-Met kinase inhibitor (IC50=46 nM) with antitumor and antiproliferative activity. Antitumor agent-111 arrests cell cycle at G0/G1 phase, and induces apoptosis [1].
    Antitumor agent-111
  • HY-147801
    Topoisomerase IIα-IN-3

    		Topoisomerase Apoptosis Cancer
    Topoisomerase IIα-IN-3 (Compound 12c) is a DNA intercalative topoisomerase-IIα inhibitor. Topoisomerase IIα-IN-3 arrests cell cycle at the G0/G1 phase and induces apoptosis [1].
    Topoisomerase IIα-IN-3
  • HY-145762
    YM281

    		Apoptosis Histone Methyltransferase Cancer
    YM281 is a potent EZH2 inhibitor. YM281 induces cell apoptosis and cell cycle arrest at the G0/G1 phase. YM281 shows antitumor effects in vivo. YM281 has the potential for the research of lymphoma [1].
    YM281
  • HY-155503
    Antitumor agent-103

    		Apoptosis Cancer
    Antitumor agent-103 (compound 24l) is an apoptosis inducer with antiproliferative and anti-clony formation activities. Antitumor agent-103 arrests cell cycle at G0/G1 phase, enhances NO production, and exhibits anti-tumor activity [1].
    Antitumor agent-103
  • HY-149063
    Antitumor agent-92

    		Apoptosis Cancer
    Antitumor agent-92, an Icaritin (HY-N0678) derivative, causes arrest at the G0/G1 phase in the cell cycle and induces cell apoptosis. Antitumor agent-92 has the potential for hepatocellular carcinoma (HCC) research [1].
    Antitumor agent-92
  • HY-159096
    Apoptosis inducer 21

    		Apoptosis Cancer
    Apoptosis inducer 21 (Compound 5h) inhibits the proliferation of lung cancer cell H69AR with an IC50 of 1.58 μM. Apoptosis inducer 21 arrests the cell cycle at G0/G1 phase, induces apoptosis in H69AR [1].
    Apoptosis inducer 21
  • HY-146040
    Anticancer agent 47

    		Apoptosis Cancer
    Anticancer agent 47 (compound 4j) is a potent anticancer agent. Anticancer agent 47 shows antiproliferative activities. Anticancer agent 47 induces apoptosis and cell cycle arrest at G0/G1 phase. Anticancer agent 47 shows shows antitumor activities in vivo [1].
    Anticancer agent 47
  • HY-146063
    Anticancer agent 54

    		Apoptosis Cancer
    Anticancer agent 54 is a potent anticancer agent. Anticancer agent 54 shows antiproliferative activity. Anticancer agent 54 induces apoptosis and cell cycle arrest at G0/G1 phases. Anticancer agent 54 shows anticancer activity depends on DNA intercalation and ROS generation [1].
    Anticancer agent 54
  • HY-P11173
    Cr-ACP1

    		DNA Alkylator/Crosslinker Apoptosis Cancer
    Cr-ACP1 is an anti-cancerous peptide. Cr-ACP1 binds to DNA, inducing cell cycle arrest in the G0-G1 phase, leading to the initiation of Apoptosis mechanisms. Cr-ACP1 exhibits anticancer effects against colon cancer and epidermoid carcinoma [1] .
    Cr-ACP1
  • HY-165064
    C2 L-Erythro ceramide (d18:1/2:0)

    L-Erythro cer(d18:1/2:0); N-Acetyl-L-erythro-sphingosine; Acetyl-L-erythro-sphingosine

    		 Apoptosis Cancer
    C2 L-Erythro ceramide (d18:1/2:0) is a cell-permeable sphingolipid. C2 L-Erythro ceramide (d18:1/2:0) induces cell cycle arrest in the G0/G1 phase and inhibits cell growth [1] .
    C2 L-Erythro ceramide (d18:1/2:0)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: